Drugs / RBS2418
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05270213 | Jul 2022 → Apr 2027 expected | cancer of unknown primary site | Riboscience, LLC. | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05683470 | — | — | Riboscience, LLC. | No longer available | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07175441 Comparator | Apr 2026 → Apr 2027 expected | hepatocellular carcinoma | Riboscience, LLC. | Recruiting | No outcome recorded |
| Phase 2 | NCT06824064 Comparator | Jan 2025 → Dec 2027 expected | colorectal cancer, metastatic malignant neoplasm in the colon | Riboscience, LLC. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-10-20 | Riboscience, LLC. | Results Riboscience presents data from an ongoing Phase 1 trial of a new immunotherapy in patients with advanced cancers riboscience.com ↗
No DLTs, no treatment-related SAEs or treatment-related AEs above grade 2 were observed for treatment durations up to 1 year. |
| 2022-06-02 | Riboscience, LLC. | Results First-in-human experience using RBS2418, an oral ENPP1 inhibitor within an expanded access protocol in combination with pembrolizumab in a patient with metastatic adrenal cancer riboscience.com ↗
All evaluated dose levels of RBS2418 in combination with pembrolizumab were found to be safe and well tolerated. |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBS2418 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06824064 ↗ |
| Action | Inhibit | “RBS2418 is a potent and selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1).” NCT05270213 ↗ |
| Modality | Small molecule | “RBS2418 is a potent and selective small molecule inhibitor” NCT05270213 ↗ |
| Route | Oral | “RBS2418 will be administered orally” NCT05683470 ↗ |
| Target | ENPP1 | “inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1)” NCT05270213 ↗ |